Cancer vaccine

Global Cancer Vaccines Market Analysis to 2026 - Featuring Aduro BioTech, Astellas Pharma & AstraZeneca Among Others - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 4:59pm

The "Global Cancer Vaccines Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccines Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cancer Vaccines market is growing at a CAGR of 18.7% from 2018 to 2026.
  • Cancer vaccines are a kind of biological treatment that avoids and heals different sorts of cancer diseases, for example, cervical cancer, prostate cancer, lung cancer, breast cancer, and others.
  • Besides, cancer vaccines are expected to decrease the prevalence and incidence rate of cancer.

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia

Wednesday, March 4, 2020 - 1:14pm

In addition, it is also involved in tumor targeting, engagement of the immune system, and induction of an anti-cancer vaccine effect.

Key Points: 
  • In addition, it is also involved in tumor targeting, engagement of the immune system, and induction of an anti-cancer vaccine effect.
  • The durability of those responses was maintained in patients months after stopping treatment suggesting a vaccine effect had occurred.
  • Shenogen Pharma Group is a drug discovery and development company founded in 2006 at Beijing, China.
  • Currently, Shenogenis establishing a full pharma value chain from research to production and commercialization.For more information, please visit www.shenogen.com .

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

Thursday, February 27, 2020 - 10:00am

Calidi Biotherapeutics , Inc. (Calidi), a clinicalstage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board .

Key Points: 
  • Calidi Biotherapeutics , Inc. (Calidi), a clinicalstage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board .
  • Peoples is a passionate leader with significant experience in cancer vaccines and a recognized authority on early oncology therapeutic development.
  • I am excited to join this incredibly focused and dedicated group of advisors, said Dr. George Peoples, MD, FACS.
  • Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the completeness or updated status of such statements.

Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer

Wednesday, February 26, 2020 - 2:00pm

The cancer tells the immune system and T cells to leave the tumor alone instead of directly attacking it.

Key Points: 
  • The cancer tells the immune system and T cells to leave the tumor alone instead of directly attacking it.
  • "There may be trials available for patients whose disease comes back, but not as many for patients just diagnosed.
  • They found that among these patients, only 11,577 (0.1%) participated in clinical trials as their first course of cancer therapy after diagnosis.
  • According to the data, clinical trial accrual in the U.S. is very low among patients with cancer compared with other developed countries.

Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer

Wednesday, February 26, 2020 - 2:00pm

The cancer tells the immune system and T cells to leave the tumor alone instead of directly attacking it.

Key Points: 
  • The cancer tells the immune system and T cells to leave the tumor alone instead of directly attacking it.
  • "There may be trials available for patients whose disease comes back, but not as many for patients just diagnosed.
  • They found that among these patients, only 11,577 (0.1%) participated in clinical trials as their first course of cancer therapy after diagnosis.
  • According to the data, clinical trial accrual in the U.S. is very low among patients with cancer compared with other developed countries.

Global Prostate Cancer Vaccines - Competitive Intelligence Analysis Featuring Pfizer, Dendreon Corporation and Bavarian Nordic - ResearchAndMarkets.com

Monday, February 17, 2020 - 11:05am

The "Prostate Cancer Vaccines - Competitive Intelligence Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prostate Cancer Vaccines - Competitive Intelligence Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into growth prospects of the Prostate Cancer Vaccines market.
  • Key Highlights Offered in the Report:
    Cancer treatment vaccines, also called therapeutic vaccines, are a type of immunotherapy.
  • The 2016 annual sales of prostate cancer vaccines was approximately USD 300 million.

Increasing Clinical Development Activities Driving the Prostate Cancer Vaccines Market

Friday, February 14, 2020 - 12:45pm

This pipeline analysis of cancer vaccines includes a product description, company description and development activities focusing on technology, designations, collaborations & licensing deals, grants, and patent details.

Key Points: 
  • This pipeline analysis of cancer vaccines includes a product description, company description and development activities focusing on technology, designations, collaborations & licensing deals, grants, and patent details.
  • Provides an overview of therapeutic pipeline activity for Prostate Cancer Vaccines across the complete product development cycle and company overview.
  • Detailed profiles of Prostate Cancer Vaccines with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations and technologies.
  • The report also covers market drivers, market barriers and market opportunities and SWOT analysis to build the in depth understanding of prostate cancer vaccines market.

Global Therapeutic Vaccines Market 2019-2023 | Evolving Opportunities with Aimmune Therapeutics Inc. and Immune Response BioPharma Inc. | Technavio

Wednesday, January 15, 2020 - 11:00pm

The cancer vaccines segment will continue to account for the highest therapeutic vaccine market share during the forecast period.

Key Points: 
  • The cancer vaccines segment will continue to account for the highest therapeutic vaccine market share during the forecast period.
  • This is attributed to the increasing prevalence of cancer and the development of therapeutic vaccines to treat cancer.
  • Therapeutic vaccines Regional Outlook (Revenue, USD Million, 2019-2023)
    The North American region led the market in 2019, followed by Europe, Asia, ROW respectively.
  • Headquartered in the US, Immune Response BioPharma Inc. offers various therapeutic vaccines, such as RAVAX, NeuroVax, Zorcell, and RemuneX.

Therapeutic & Preventive Vaccine Market Study, 2019-2025 - Analysis by Type, End-user and Region

Friday, January 10, 2020 - 9:00pm

The global therapeutic and preventive vaccine market is segmented on the basis of type, end-user, and region.

Key Points: 
  • The global therapeutic and preventive vaccine market is segmented on the basis of type, end-user, and region.
  • On the basis of disease, the therapeutic vaccine market is sub-segmented into autoimmune disease vaccine, neurological disease vaccine, and cancer vaccine.
  • Analysis of regional regulations and other government policies impacting the global therapeutic and preventive vaccine market.
  • Insights about market determinants which are stimulating the global therapeutic and preventive vaccine market.